Impact of alirocumab on lipid profile in patients with type 2 diabetes

  • Colhoun HM & al.
  • Cardiovasc Diabetol
  • 8 Feb 2020

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with type 2 diabetes mellitus (T2DM) who were at high cardiovascular risk, alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB) and LDL particle number and significantly increased HDL-C compared with usual care overall.
  • Reduction in ApoB was greater with alirocumab compared with ezetimibe, fenofibrate or no additional lipid-lowering therapy.

Why this matters

  • ODYSSEY DM-DYSLIPIDEMIA trial showed that alirocumab was superior to usual care overall in reducing non-HDL-C vs fenofibrate and was generally well tolerated.

Study design

  • A post-hoc analysis of ODYSSEY DM-DYSLIPIDEMIA trial included 186 patients with T2DM who were randomly assigned to receive alirocumab (n=128) or usual care (n=58).
  • Primary outcome: percentage change in LDL-C, non-HDL-C, ApoB, LDL particle number, lipoprotein (a) [Lp (a)], triglycerides (TGs), TG-rich lipoprotein (TRL) and HDL-C.
  • Funding: Sanofi and Regeneron Pharmaceuticals, Inc.

Key results

  • From baseline to 24 weeks, alirocumab vs usual care significantly reduced the risk for:
    • non-HDL-C (least square [LS] mean difference standard error [SE], −35.0% [3.9]);
    • ApoB (LS mean difference [SE], −34.7% [3.6]);
    • LDL-C (LS mean difference [SE], −47.3% [5.2]);
    • LDL particle number (LS mean difference [SE], −40.8% [4.1]); and
    • Lp(a) (LS mean difference [SE], −29.9% [5.4]); P<.0001 for all.>
  • Fenofibrate was associated with a reduction in TGs vs usual care (LS mean difference [SE], 9.6% [10.0]; P=.3371).
  • Overall, alirocumab significantly increased HDL-C vs usual care (LS mean difference [SE], 7.9% [3.6]; P=.0295).
  • Patients who received ralirocumab achieved ApoB
  • No difference was observed in TGs and adverse event frequency between alirocumab (67.2%) and usual care (70.7%).
  • Alirocumab did not show any effects on glycaemic parameters or use of antihyperglycaemic agents.

Limitations

  • Post-hoc analysis.